SicaGene is a biotech company focused on the research and development of next-generation antisense oligonucleotide (ASO) drugs.The founding team comes from leading international biotechnology companies such as BeiGene and Ionis, with extensive experience in oligonucleotide drug development, clinical trials, and regulatory affairs. Small interfering RNA (siRNA) drugs primarily target specific mRNA molecules through base complementarity, interfering with mRNA translation efficiency to influence the expression of target proteins and ultimately achieve therapeutic effects.In recent years, small nucleic acid drugs have gained significant attention in the biopharmaceutical field due to their high specificity, simplicity of design, short development cycles, and abundance of target molecules. Among these, antisense oligonucleotides (ASOs) represent the most mature technology platform, with ASO drug sales reaching approximately $3.2 billion in 2023 alone, signifying one of the key directions for the future development of small nucleic acid drugs.However, no domestic company has yet brought a product to market. Based on its professional basic research, Siheng Gene has established self-developed platforms including a high-efficiency sequence design platform, a nucleic acid combination modification platform, and an innovative delivery system, enabling efficient screening of drug targets, reducing development difficulty and costs, and achieving scalable and standardized development of oligonucleotide drugs.Currently, the company focuses on drug development for difficult-to-treat diseases such as liver diseases and other metabolic disorders, ophthalmology, and the central nervous system, with multiple compounds already in preclinical research stages. Since its establishment, the company has been honored with multiple awards, including “National High-Tech Enterprise” and “Zhongguancun High-Tech Enterprise.”